This review outlines the most common causes of resistance to anti-PD-1/PD-L1 immunotherapy in GBM and mechanisms to enhance the efficacy of these agents, especially through combination with other treatment modalities and/or standard GBM therapy, as well as recently published clinical trial outcomes of GBM immunotherapy. This evidence concerns the gene CD274 and glioblastoma.